SMD (Surface Mount Device) terahertz intelligent pulse massage instrument and control method thereof

Abstract

The invention belongs to the technical field of massage instruments, and particularly relates to a patch type terahertz intelligent pulse massage instrument and a control method thereof.The patch type terahertz intelligent pulse massage instrument comprises an electrode patch, a data processing module, an intelligent analysis module, a massage instrument control module, a massage instrument safety monitoring module and a massage instrument applet / APP; terahertz wave biological regulation and control and intelligent pulse current are combined, transdermal drug delivery is synchronously achieved, a composite therapy of physical stimulation and drug intervention is formed, muscle states are graded in real time through the myoelectricity activity index, transdermal efficiency is quantified through the drug permeation index, pulse parameters and the drug delivery rate are dynamically adjusted, and terahertz waves deeply penetrate subcutaneous tissue, so that the treatment effect is achieved. The drug transdermal rate is enhanced in cooperation with micro-current, fusing protection is triggered by abnormal data, cloud historical data analysis is combined, the risk of overstimulation is reduced, a user physiological response model and preference data are stored, a control strategy is continuously optimized through machine learning, and individual differences are adapted.

Description

Technical Field

[0001] The present invention belongs to the field of massagers, and in particular relates to a massager control method. The present invention specifically discloses a patch-type terahertz intelligent pulse massager and a control method thereof. Background Art

[0002] Long-term desk work and the expansion of the phone-dwelling population have led to a surge in the number of people suffering from shoulder and neck strain. More than 60% of adults worldwide suffer from muscle strain, creating a demand for portable physiotherapy equipment.

[0003] Patch-type massagers achieve physical therapy effects by stimulating the neuromuscular system through electrical pulses. The host circuit generates low-frequency or medium-frequency pulse currents, which are transmitted to electrode patches through wires. The patches are made of conductive silicone or hydrogel materials to ensure that the current is evenly distributed to the skin surface, reducing contact impedance. The pulse current directly stimulates motor neurons, triggering rhythmic muscle contraction and relaxation, simulating manual massage, promoting local blood circulation and lactic acid metabolism. Specific frequency pulses interfere with pain nerve signal transmission, temporarily suppressing pain perception. They are suitable for relieving acute pain, but the following problems still exist:

[0004] Functional singleness defect: It only relies on electrical pulse stimulation and lacks multimodal collaborative treatment methods such as terahertz waves and drug transdermal therapy, resulting in low rehabilitation efficiency.

[0005] Static parameter limitations: It uses fixed frequency and intensity output and cannot be dynamically adjusted according to the electromyographic signal, causing users to experience tingling or ineffective treatment due to parameter discomfort.

[0006] Low transdermal efficiency: The traditional iontophoresis method has insufficient drug penetration rate, and the electrode-skin contact impedance increases significantly with the use time, affecting the sustainability of the therapeutic effect.

[0007] Weak safety protection: Protection is achieved only through basic current limitation, lacks real-time biofeedback and fuse mechanism, and has a high incidence of clinical adverse reactions.

[0008] No personalized adaptation: There is no user data storage and learning capabilities. All users use the same preset mode and cannot adapt to differentiated needs such as chronic pain and sports recovery.

[0009] Therefore, multimodal collaborative treatment, dynamic closed-loop regulation, non-invasive and efficient penetration, intelligent security protection and cloud-based personalized optimization methods are needed to solve the above problems. Summary of the Invention

[0010] In view of this, the present invention proposes a patch-type terahertz intelligent pulse massager and a control method thereof. The patch-type terahertz intelligent pulse massager collects myoelectric activity and drug release data in real time through electrode patches, generates an electromyographic activity index and a drug penetration index through a data processing module, and the intelligent analysis module divides the muscle state level and drug penetration efficiency grade accordingly. The massager control module outputs personalized pulse parameters and drug delivery rate, triggers fuse protection and alarms in case of abnormalities, and finally realizes closed-loop control of terahertz wave stimulation and transdermal drug delivery through cloud-based collaborative optimization of user-exclusive physical therapy strategies.

[0011] The purpose of the present invention can be achieved by the following technical solution: A control method for a patch-type terahertz intelligent pulse massager, specifically comprising the following steps:

[0012] S1, collects multi-source data through electrode patches, including data related to electromyographic activity and drug release;

[0013] S2. Generate an electromyographic activity index and a drug penetration index through a data processing module based on the collected data;

[0014] S3. Using the intelligent analysis module to distinguish muscle status levels based on the myoelectric activity index and to perform penetration grading based on the drug penetration index;

[0015] S4. Dynamically output parameters through the massager control module based on the intelligent analysis results. The massager control module includes a pulse parameter generation unit and an intelligent drug delivery execution unit.

[0016] S5. When the data is abnormal, the massager safety monitoring module will perform fuse protection and abnormal alarm;

[0017] S6. Store user historical mode preferences and physiological response models through the massager mini program / APP to continuously optimize the control strategy.

[0018] A patch-type terahertz intelligent pulse massager, specifically comprising:

[0019] Electrode patches: used to collect data related to myoelectric activity and drug release in real time;

[0020] Data processing module: used to generate myoelectric activity index and drug penetration index based on the collected myoelectric activity related data and drug release related data;

[0021] Intelligent analysis module: used to distinguish muscle status levels based on myoelectric activity index and perform penetration grading based on drug penetration index;

[0022] Massager control module: used to dynamically output parameters based on intelligent analysis results, including a pulse parameter generation unit and an intelligent drug delivery execution unit;

[0023] Massager safety monitoring module: used to provide fuse protection and abnormal alarm when data abnormality is detected;

[0024] Massager applet / APP: used to store user historical mode preferences and physiological response models, and continuously optimize control strategies.

[0025] Combining all the above technical solutions, the present invention has the following positive effects:

[0026] 1. The present invention combines terahertz wave bioregulation with intelligent pulse current to synchronously achieve transdermal drug delivery, forming a combined therapy of "physical stimulation + drug intervention".

[0027] 2. The present invention uses the myoelectric activity index to classify muscle status in real time, the drug penetration index to quantify transdermal efficiency, and dynamically adjusts pulse parameters and drug delivery rate, avoiding the extensive problem of fixed parameters in traditional equipment.

[0028] 3. The terahertz waves of the present invention penetrate deeply into the subcutaneous tissue, and cooperate with the microcurrent to enhance the drug penetration rate, thereby avoiding the risk of skin damage caused by the microneedle array.

[0029] 4. Abnormal data in the present invention triggers fuse protection, which is combined with cloud historical data analysis to reduce the risk of over-stimulation.

[0030] 5. Store user physiological response models and preference data, and continuously optimize control strategies through machine learning to adapt to individual differences. BRIEF DESCRIPTION OF THE DRAWINGS

[0031] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the following briefly introduces the drawings required for describing the embodiments. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without creative work.

[0032] Attachment Figure 1 This is a system block diagram of the present invention.

[0033] Attachment Figure 2 Flowchart of the present invention. DETAILED DESCRIPTION

[0034] The technical solutions of the present invention will be clearly and completely described below in conjunction with the embodiments. Obviously, the described embodiments are only a part of the embodiments of the present invention, rather than all the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative work are within the scope of protection of the present invention.

[0035] See also Figure 1As shown, the present invention proposes a patch-type terahertz intelligent pulse massager, which includes an electrode patch, a data processing module, an intelligent analysis module, a massager control module, a massager safety monitoring module and a massager applet / APP.

[0036] like Figure 2 As shown, the present invention proposes a control method for a patch-type terahertz intelligent pulse massager, and the specific implementation steps include the following steps:

[0037] S1. Collect multi-source data through electrode patches, including data related to electromyographic activity and drug release.

[0038] It should be noted that the electromyographic activity data specifically includes:

[0039] Root mean square value: reflects the amplitude strength of the electrical signal during muscle contraction;

[0040] Integrated EMG value: represents the total electrical activity of sustained muscle contraction;

[0041] Median frequency: a characteristic indicator of the left shift of the spectrum during muscle fatigue;

[0042] Average power frequency: the frequency of the center of gravity of energy distribution, which is related to the accumulation of metabolites.

[0043] It should be noted that the drug release related data specifically include:

[0044] Initial impedance: The baseline resistance value of biological tissue when no intervention is applied, reflecting the integrity of the skin stratum corneum and the water content of the tissue;

[0045] Real-time impedance: The impedance change value during dynamic monitoring is directly related to the movement of tissue fluid and changes in cell membrane permeability;

[0046] Drug penetration activation energy: the minimum energy threshold required for drug molecules to break through the skin barrier, which represents the difficulty of penetration;

[0047] Measured body surface temperature: The actual temperature of the skin surface directly affects the drug diffusion coefficient;

[0048] Normalized blood flow velocity: microcirculatory blood flow rate corrected by body surface temperature, reflecting the efficiency of drug distribution throughout the body;

[0049] Cumulative drug release: the total amount of drug absorbed by a unit area of skin within a specified time;

[0050] Release time: the duration from the start of drug administration to the reaching of target blood drug concentration.

[0051] S2. Generate the myoelectric activity index and drug penetration index through the data processing module according to the collected data.

[0052] It should be noted that the myoelectric activity index is specifically:

[0053]

[0054] Among them, J is the electromyographic activity index, which reflects the intensity of muscle electrical activity and quantifies the comprehensive state of muscle function; H is the activation index, which reflects the degree of muscle nerve excitation, quantifies the intensity of nerve drive, and provides positive stimulation. The larger the value, the higher the degree of muscle activation; P is the fatigue index, which characterizes the degree of accumulation of metabolic products, quantifies the degree of inhibition, and applies fatigue attenuation. The larger the value, the deeper the fatigue; k is the coupling coefficient, which reflects the intensity of fatigue inhibition and controls the degree of electrical-mechanical separation, and ranges from 1.5 to 1.6.

[0055] It should be explained that the activation index is specifically:

[0056]

[0057] Where Z is the amplitude of the electromyographic signal, which directly reflects the instantaneous contraction force of the muscle; Z max is the amplitude of the electromyographic signal during maximum voluntary contraction, representing the peak muscle capacity; α is the contribution of instantaneous contraction, controlling spasm sensitivity; D is the total amount of electrical activity per unit time, representing the sustained contraction capacity; D max is the limit of continuous contraction, indicating the endurance benchmark; β is the contribution to continuous contraction, which prevents misjudgment of short-term fluctuations; the range of α is 0.6-0.65, and the range of β is 0.35-0.4, which can be adaptively adjusted dynamically.

[0058] It should be explained that the fatigue index is specifically:

[0059]

[0060] Where G is the median frequency of the power spectrum, reflecting the state of fast muscle fibers, which decreases significantly when metabolites accumulate; G r is the median frequency in the resting state, reflecting the basal metabolic level of the muscle and serving as an individual fatigue benchmark; γ is the metabolic fatigue sensitivity, capturing early fatigue; F is the center of gravity of the spectrum energy distribution, which shifts to the left when the muscle fiber conduction velocity decreases, representing the conduction velocity; F r is the center of gravity of the spectrum in the resting state, reflecting the basic conduction state and serving as the spectrum offset benchmark; δ is the conduction fatigue sensitivity, used to detect late fatigue; the range of γ is 0.7-0.75, and the range of δ is 0.25-0.3.

[0061] It should be noted that the drug penetration index is specifically:

[0062] Y=Z χ *T μ *Kλ *(1+η*v);

[0063] Where Y is the drug permeability index, Z is the skin impedance correction factor, which characterizes the change in stratum corneum hydration. The smaller the impedance, the larger the intercellular gap and the greater the drug openness. T is the temperature increase coefficient. Based on the principle of molecular thermal motion, the higher the temperature, the greater the kinetic energy of the drug molecules, and the transmembrane diffusion rate increases exponentially. K is the drug release rate constant, which reflects the release dynamics of the drug in the carrier. The larger the K value, the greater the amount of drug released per unit time, and the larger the base amount of drug available for penetration. v is the standardized blood flow velocity, which affects the drug clearance rate in the dermis. The larger the v value, the faster the drug clearance from the skin capillaries and the higher the gradient concentration.

[0064] It should be noted that impedance change is the core bottleneck of transdermal efficiency and plays a dominant role, with its weight χ ranging from 0.45 to 0.5; temperature produces nonlinear enhancement by changing molecular dynamics, with its weight μ ranging from 0.3 to 0.35; the drug release rate constant provides the basis for drug supply, but is limited by the carrier, with its weight λ ranging from 0.15 to 0.2; the blood flow velocity v indirectly affects permeation through concentration gradient regulation, with its weight η ranging from 0.1 to 0.15.

[0065] It should be explained that the skin impedance correction factor is specifically:

[0066]

[0067] where R o is the initial skin impedance, which is the reference value; R a It is the real-time detection of skin impedance; when Z>0, it means that the impedance decreases, the hydration of the stratum corneum increases, and the drug penetration is promoted.

[0068] The temperature enhancement coefficient is specifically:

[0069]

[0070] Among them E a is the drug penetration activation energy, which is related to the molecular characteristics of the ingredients, E a The lower the value, the stronger the temperature sensitivity; T r is the reference temperature; T a is the measured surface temperature; R is the gas constant; when T a ≥T r When the temperature is high, the thermosensitive hydrogel phase change is triggered, which increases the T value and the diffusion rate.

[0071] The release rate constant is:

[0072]

[0073] Where M is the cumulative drug release within time t; t is the release time; the K value is inversely proportional to the square root of time, reflecting the sustained release process of the drug from the matrix to the skin layer.

[0074] S3. The intelligent analysis module distinguishes muscle status according to the myoelectric activity index and classifies the drugs according to the drug penetration index.

[0075] It should be noted that the muscle condition classification is specifically as follows:

[0076] When J>x1, the muscle is in a high-intensity tension state, indicating muscle spasm or overactivation;

[0077] When x2≤J<x1, the muscle is in a normal activity state, indicating that the muscle is functionally contracted;

[0078] When x3≤J<x2, the muscle is in the initial fatigue state, indicating that metabolic products begin to accumulate;

[0079] When J < x3, the muscle is in a state of significant fatigue, indicating that the spectrum shifts significantly to the left and the force output decreases;

[0080] The value range of x1 is between 0.8 and 0.9; the value range of x2 is between 0.5 and 0.6; and the value range of x3 is between 0.3 and 0.4.

[0081] It should be noted that the drug permeation classification is as follows:

[0082] When Y>y1, it is super-efficient penetration;

[0083] When y2≤Y<y1, it is ideal penetration;

[0084] When y3≤Y<y2, it is medium penetration;

[0085] When Y<y3, it is inefficient penetration;

[0086] The value range of y1 is between 1.2 and 1.3; the value range of y2 is between 0.8 and 0.9; and the value range of y3 is between 0.5 and 0.6.

[0087] S4. According to the intelligent analysis results, the massager control module dynamically outputs parameters. The massager control module includes a pulse parameter generation unit and an intelligent drug delivery actuator.

[0088] It should be noted that the output parameters of the pulse parameter generation unit are specifically:

[0089] When the muscles are in a state of high-intensity tension, the current intensity is 20-30mA, which performs inhibitory stimulation. The strong current blocks the conduction of abnormal nerve impulses, inhibits pain input, relieves spasms, and eliminates muscle tremors.

[0090] The pulse frequency is 50-100 Hz. High frequency inhibits the release of presynaptic membrane substances, reduces the excitability of motor neurons, and reduces the tension of spastic muscle groups.

[0091] The waveform is a bidirectional square wave, which rapidly depolarizes to block high-frequency abnormal discharges and adopts a burst mode to reduce the frequency of spasm attacks.

[0092] When the muscle is in a normal state of activity, the current intensity is 10-15mA, which provides maintenance stimulation, increases muscle force output, and prolongs sustained contraction time;

[0093] The pulse frequency is 20-50Hz, resonating the muscle elastic components, optimizing the synchronization of sarcomere contraction, increasing muscle work efficiency, and improving the coordination index;

[0094] The waveform is a sine wave, and continuous harmonic resonance reduces the loss of cell membrane capacitance effect. The continuous output mode is adopted to improve energy transmission efficiency.

[0095] When the muscles are in the initial fatigue state, the current intensity is 5-8mA, which provides restorative stimulation, enhances microcirculation, accelerates lactic acid clearance, and improves fatigue recovery speed;

[0096] The pulse frequency is 5-15Hz, triggering slow oscillation blood flow, enhancing tissue oxygenation, increasing blood oxygen saturation, and accelerating the rate of hemoglobin reoxygenation;

[0097] The waveform is a triangular wave, which enhances the activity of the sarcoplasmic reticulum calcium pump. It adopts an intermittent mode to increase the amplitude of calcium transients in muscle fibers and prolong the duration of contraction force.

[0098] When the muscles are in a state of significant fatigue, the current intensity is 2-4mA, which performs microcurrent repair, activates cell membrane enzyme activity, relieves delayed soreness, and reduces creatinine enzyme levels;

[0099] The pulse frequency is 1-5Hz, which activates pathways, inhibits inflammatory signals, reduces inflammatory factors, and increases muscle repair markers;

[0100] The waveform is an exponential decay wave, and the low-pass filtering characteristics target and activate fibers, regulate pain sensation, perform ultra-low frequency circulation, increase the release of endocannabinoids, and prolong the duration of analgesia.

[0101] It should be noted that the output parameters of the intelligent drug delivery actuator are as follows:

[0102] When drug penetration is ultra-efficient, the release rate is 50-100 μg / cm2·h. Nanoemulsions / ethosomes are used to fuse the keratinocyte membrane through the phospholipid bilayer to achieve endocytic transport, shorten the time it takes for blood drug concentration to reach the therapeutic window, and reduce the 24-hour sustained-release fluctuation rate.

[0103] Nanocarriers are used to directly penetrate the intercellular spaces of the stratum corneum, and electroporation is combined to improve efficiency. Cell-penetrating peptides are coupled to allow penetration depth to reach the dermis, thereby increasing the efficiency of breaking through the stratum corneum barrier.

[0104] When drug penetration is ideal, the release rate is 20-50 μg / cm2·h. Using a microneedle array / thermosensitive gel, the microneedles create microchannels, and the thermosensitive gel accelerates diffusion, increasing local tissue drug accumulation and reducing the incidence of systemic side effects.

[0105] It achieves sustained release through the hair follicle-sebaceous gland unit, with continuous release for 48 hours, reducing the recurrence rate.

[0106] When the drug permeability is moderate, the release rate is 5-20 μg / cm2·h. Using liposome-cyclodextrin inclusion complex, the liposome penetrates through the hair follicle pathway, and the hair follicle targeted delivery makes the sebaceous gland drug concentration reach n times the blood concentration;

[0107] The hair follicle-targeted penetration combined with azone penetration enhancer is used to increase the lipid fluidity of the stratum corneum and compensate for the penetration in areas with insufficient hair follicle density.

[0108] When drug penetration is low, the release rate is 1-5 μg / cm2·h. Ordinary patches / O / W creams rely on passive diffusion and need to be combined with iontophoresis to increase penetration and reduce drug residues in the stratum corneum.

[0109] The use of a combination of menthol and azone increases the fluidity of stratum corneum lipids, and low-frequency ultrasound produces a cavitation effect to expand the intercellular space, thereby improving the transdermal rate of fat-soluble drugs after combined with a penetration enhancer.

[0110] S5. The massager safety monitoring module performs fuse protection and abnormal alarm when data is abnormal.

[0111] It should be noted that the fuse protection mechanism has multiple trigger conditions, including current overload, temperature anomaly and impedance mutation, specifically:

[0112] Current overload: Current density > a mA / cm 2 Lasts 10 seconds.

[0113] Temperature abnormality: skin temperature ≥ b℃ or temperature rise > c℃ within 5 minutes;

[0114] Impedance mutation: The rate of change of tissue impedance exceeds the baseline value ±d%;

[0115] The value range of a is 0.8-1; the value range of b is 41-42; the value range of c is 3-5; and the value range of d is 25-30.

[0116] The specific risk level trigger threshold graded response strategy is as follows:

[0117] If a single parameter exceeds the limit at the first level, the power will be reduced by 50% and an audible and visual alarm will be activated;

[0118] If the secondary dual parameters exceed the limit, power will be cut off immediately and cooling gel will be released;

[0119] A level 3 impedance drop > 40% activates the backup power supply to maintain ECG monitoring and simultaneously sends the GPS location to the emergency center.

[0120] It should be noted that double verification is required after the fault is eliminated, the impedance must return to the baseline ±e% and the temperature must be <f℃. Manual restart requires three bio-impedance confirmations to prevent accidental touches; the range of e is 15-20, and the range of f is 37.5-38.

[0121] S6. Store user historical mode preferences and physiological response models through the massager mini program / APP to continuously optimize the control strategy.

[0122] The massager mini program / APP includes core architecture layering, key function extensions and enhanced technical components.

[0123] The core architecture is divided into:

[0124] Real-time processing at the edge layer: Deploy models to process sensor data streams, use a ring buffer to store the last 30 seconds of data, and support an abnormal data fusing mechanism;

[0125] Transport layer security synchronization: adding noise to protect physiological data privacy, switching formats based on network quality, and reducing bandwidth;

[0126] Cloud-layer model optimization: Aggregate data from millions of users to update the global model, without leaving the local data domain, and associate user behavior logs, environmental data, and physiological indicators to build a causal inference network.

[0127] The key functional extensions are specifically:

[0128] Preference prediction: Use time series analysis to analyze historical operation sequences and improve the accuracy of predicting the next operation;

[0129] Physiological model iteration: Based on personalized physiological response simulator, the error rate of the general model is reduced;

[0130] Policy Optimizer: Multi-objective reinforcement learning to balance comfort and energy consumption;

[0131] Cross-device collaboration: Use protocols to synchronize smart home and wearable device commands.

[0132] The enhanced technical components are specifically:

[0133] Edge-cloud load balancing: Calculates network status scores in real time and dynamically allocates computing tasks; launches cloud sandbox containers in the event of traffic bursts, seamlessly taking over overloaded tasks at the edge layer;

[0134] Zero-trust security system: device fingerprint authentication, behavioral baseline anomaly detection;

[0135] Offline emergency mode: A local lightweight decision tree ensures the operation of basic functions during network outages.

[0136] Through the description of the above embodiments, those skilled in the art can clearly understand that the various embodiments of the present application can be implemented by means of software or software combined with a necessary general hardware platform, and of course can also be implemented by hardware functions; based on such understanding, the technical solution of the present application can essentially be embodied in the form of a software product or the part that contributes to the prior art. The software product is stored in a storage medium and includes a number of instructions for enabling a computer device, such as but not limited to a personal computer, a server, or a network device, to execute all or part of the steps of the method described in any embodiment of the present application.

[0137] The above describes exemplary embodiments of the present application. It should be understood that the above exemplary embodiments are not restrictive but illustrative, and the scope of protection of the present application is not limited thereto. It should be understood that those skilled in the art can modify and vary the embodiments of the present application without departing from the spirit and scope of the present application, and these modifications and variations should be within the scope of protection of the present application.

Claims

1. A control method for a patch-type terahertz intelligent pulse massager, characterized in that: The specific steps include: S1, collects multi-source data through electrode patches, including data related to electromyographic activity and drug release; S2. Generate an electromyographic activity index and a drug penetration index through a data processing module based on the collected data; S3. Using the intelligent analysis module to distinguish muscle status levels based on the myoelectric activity index and to perform penetration grading based on the drug penetration index; S4. Dynamically output parameters through the massager control module based on the intelligent analysis results. The massager control module includes a pulse parameter generation unit and an intelligent drug delivery execution unit. S5. When the data is abnormal, the massager safety monitoring module will perform fuse protection and abnormal alarm; S6. Store user historical mode preferences and physiological response models through the massager mini program / APP to continuously optimize the control strategy.

2. The control method of a patch-type terahertz intelligent pulse massager according to claim 1, characterized in that: The myoelectric activity related data specifically include root mean square value, integrated myoelectric value, median frequency and average power frequency; The drug release related data specifically include initial impedance, real-time impedance, drug penetration activation energy, measured body surface temperature, normalized blood flow velocity, cumulative drug release amount and release time.

3. The control method of a patch-type terahertz intelligent pulse massager according to claim 1, characterized in that: The myoelectric activity index is specifically: Where J is the myoelectric activity index; H is the activation index; P is the fatigue index; and k is the coupling coefficient.

4. The control method of a patch-type terahertz intelligent pulse massager according to claim 3, characterized in that: The activation index is specifically: Where Z is the amplitude strength of the electromyographic signal; Z max is the amplitude of the electromyographic signal during maximum voluntary contraction; α is the contribution of instantaneous contraction; D is the total amount of electrical activity per unit time; D max is the limit of continuous contraction; β is the contribution of continuous contraction; The fatigue index is specifically: Where G is the median frequency of the power spectrum; G r is the median frequency in the resting state; γ is the sensitivity to metabolic fatigue; F is the center of gravity of the spectrum energy distribution; F r is the center of gravity of the spectrum in the resting state; δ is the conduction fatigue sensitivity.

5. The control method of a patch-type terahertz intelligent pulse massager according to claim 1, characterized in that: The drug penetration index is specifically: Y=Z χ *T μ *K λ *(1+η*v); where Y is the drug permeability index; Z is the skin impedance correction factor; T is the temperature increase coefficient; K is the drug release rate constant; v is the normalized blood flow velocity; χ, μ, λ, and η are weights.

6. The control method of a patch-type terahertz intelligent pulse massager according to claim 5, characterized in that: The skin impedance correction factor is specifically: where R o is the initial skin impedance; R a For real-time detection of skin impedance; The temperature enhancement coefficient is specifically: Among them E a is the drug penetration activation energy; T r is the reference temperature; T a is the measured body surface temperature; R is the gas constant; The release rate constant is specifically: Where M is the cumulative drug release within time t; t is the release time.

7. The control method of a patch-type terahertz intelligent pulse massager according to claim 1, characterized in that: The muscle condition classification is specifically as follows: When J>x1, the muscle is in a high-intensity tension state; When x2≤J<x1, the muscle is in normal activity state; When x3≤J<x2, the muscle is in the initial fatigue state; When J < x3, the muscle is in a state of significant fatigue; The drug penetration classification is specifically: When Y>y1, it is super-efficient penetration; When y2≤Y<y1, it is ideal penetration; When y3≤Y<y2, it is medium penetration; When Y<y3, it is inefficient penetration.

8. A patch-type terahertz intelligent pulse massager, a control method for a patch-type terahertz intelligent pulse massager according to any one of claims 1 to 7, characterized in that: Specifically include: Electrode patches: used to collect data related to myoelectric activity and drug release in real time; Data processing module: used to generate myoelectric activity index and drug penetration index based on the collected myoelectric activity related data and drug release related data; Intelligent analysis module: used to distinguish muscle status levels based on myoelectric activity index and perform penetration grading based on drug penetration index; Massager control module: used to dynamically output parameters based on intelligent analysis results, including a pulse parameter generation unit and an intelligent drug delivery execution unit; Massager safety monitoring module: used to provide fuse protection and abnormal alarm when data abnormality is detected; Massager applet / APP: used to store user historical mode preferences and physiological response models, and continuously optimize control strategies.

Images